Effect For Double Dose Of Coenzyme Q₁₀ To Prevent Hepatic Injury From Double Dose Of Rosuvastatin

Objective: To evaluate the impact of rosuvastatin20mg once per nighton liver functions of the patients who had taken common dose statins or hadnever taken statins before treatment. To observe whether these changes wouldrelate to the patients having taken common dose statins or never beforetreatment. Furthermore, to determine whether double dose of coenzyme Q₁₀supplementation would prevent statin-induced hepatopathy, and whether itinfluence anti-inflammatory.Methods：The patients（including the patients who had taken commondose of statins or had never taken statins） who were diagnosed as coronaryheart disease in the Second Hospital of Hebei Medical University from July2012to December2012were collected. The number of patients was98,including57male cases,41female cases. all of them were divided into twogroups according to whether they had taken statins：group one were patientswho had never taken statins and patients in group two had taken common doseof statins.each of them was divided into two groups randomly. Group onewere divided into statins group one, including24patients aged41～69（58.3±5.8）years old, Statins and coenzyme group one including26patients aged34～75（52.7±8.1）years old. Group two were divided into statins group two,including27patients aged42～74（58.7±8.6）years old; statins and coenzymegroup two, including21patients aged50～85（62.8±8.7）years old. statinsgroups were treated with rosuvastatin20mg once per night.; Statins andcoenzyme groups were treated with rosuvastatin20mg once per night andcoenzyme Q₁₀40mg Tid. The liver functions and blood routine and hs-CRP ofthe patients were measured before administration and after1,4weeks.Rosuvastatin was suspended when transaminase levels rised to three times theupper limit of normal. Exclusion criteria: the women who are pregnanting, breastfeeding and planning pregnancy,the patients with acute myocardialinfraction, cholestasis, active liver disease, serious metabolic abnormalities ofthe kidney or liver, drinking heavily associated with concentration of statinsplasma, severe acute infection, hypotension, major surgery, trauma, severemetabolic and endocrine disorders, electrolyte imbalance, uncontrolledepilepsy, and those allergy to statins. The data were analyzed by SSPS19.0statistical software.Results：1. In statins group one, the ALT levels at one week and onemonth after treatment were significantly higher than ALT before therapy, butthere was not significantly higher for the ALT levels one month than ALT atone week after treatment. In statins group two, ALT increased significantly atone week after treatment, while the ALT levels were not significantly higher atone month after treatment than that before therapy, and the ALT levels at onemonth were not lower significantly than that at one week after treatment.In statins group one, the AST levels at one week and one month aftertreatment were significantly higher than that before therapy, but there was notsignificantly higher for the AST levels at one month than AST at one weekafter treatment. In statins group two, AST increased significantly at one weekafter treatment, while the AST levels were not significantly higher at onemonth after treatment than AST before therapy, and the AST levels at onemonth were not lower significantly than AST at one week after treatment.2.10.4%patients in statins group one transaminase were two times theupper limit of normal at1week after treatment, while there were25.0%patients whose transaminase were three times the upper limit of normal.Furthermore, after one month14.6%,29.2%patients transaminase were twotimes, three times the upper limit of normal. Comparatively,5.6%patients instatins group two, transaminase were two times the upper limit of normal at1week after treatment, while there were5.6%, whose transaminase were threetimes the upper limit of normal. And transaminase for5.6,9.3%patients weretwo times, there times the upper limit of normal after one month.Comparing statins group one with statins group two, it could prevent the ration of two times the upper limit of normal for AST、ALT, and the chang ofthem whether the patients had taken common dose of statins,but the influencewas significant to the ration of three times the upper limit of normal for AST.3. Comparing statins group one with Statins and coenzyme group one,double dose of coenzyme Q₁₀could significantly prevent the elevation ofALT、AST, but it didn’t reduce the two and three times the upper limit ofnormal for AST、 ALT. Comparing statins group two with Statins andcoenzyme group two, double dose of coenzyme Q₁₀could significantlyprevent the elevation of ALT, while it did not prevent the elevation of ASTsignificantly. Otherwise, it didn’t reduce the two and three times the upperlimit of normal for AST、ALT.4. The hs-CRP levels after treatment were not lower significantly than thelevels before therapy in statins group one and statins group two. Comparingstatins group one with Statins and coenzyme group one, double dose ofcoenzyme Q₁₀couldn’t significantlly affect the change of the hs-CRP levels.Conclusion:1. The level of transaminase would elevate significantly atone week after the patients who had taken common dose of statins or hadnever taken statins and it would be higer at one month after treetment.2. It could not prevent the chang of transaminase and the two and threetimes the upper limit of normal for AST、ALT if the patients had takencommon dose of statins before the treatmemt.3. Double dose of coenzyme Q₁₀could significantly prevent thestatin-induced hepatopathy when people who had never taken statins weregiven double dose of statins. And it also could significantly prevent theelevation of ALT,but it couldn’t significantly prevent the elevation of AST.4.Double dose statins couldn’t effectively reduce the level of hs-CRP, andthere was no anti-inflammatory action of the double dose of coenzyme Q₁₀.